+

WO1998036067A9 - Proteines secretees et polynucleotides les codant - Google Patents

Proteines secretees et polynucleotides les codant

Info

Publication number
WO1998036067A9
WO1998036067A9 PCT/US1998/002767 US9802767W WO9836067A9 WO 1998036067 A9 WO1998036067 A9 WO 1998036067A9 US 9802767 W US9802767 W US 9802767W WO 9836067 A9 WO9836067 A9 WO 9836067A9
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotide
seq
protein
amino acid
nucleotide
Prior art date
Application number
PCT/US1998/002767
Other languages
English (en)
Other versions
WO1998036067A3 (fr
WO1998036067A2 (fr
Filing date
Publication date
Application filed filed Critical
Priority to EP98906384A priority Critical patent/EP0981612A2/fr
Priority to JP53592498A priority patent/JP2002514070A/ja
Priority to AU61622/98A priority patent/AU6162298A/en
Priority to CA002280968A priority patent/CA2280968A1/fr
Publication of WO1998036067A2 publication Critical patent/WO1998036067A2/fr
Publication of WO1998036067A3 publication Critical patent/WO1998036067A3/fr
Publication of WO1998036067A9 publication Critical patent/WO1998036067A9/fr

Links

Definitions

  • the present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • SEQ ID NO:6 The predicted amino acid sequence of the BK34_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6. Additional nucleotide sequence from the 3' portion of BK34_3/ including the polyA tail, is reported in SEQ ID NO:7.
  • CT24_3 The nucleotide sequence of CT24_3 as presently determined is reported in SEQ ID NO:14. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CT24_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:15. Amino acids 10 to 22 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23, or are a transmembrane domain.
  • the invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous, or related to that encoded by the polynucleotides .
  • polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below.
  • Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).
  • the polynucleotides provided by the present invention can be used by the research community for various purposes.
  • the polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip” or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques;
  • infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis.
  • a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.
  • up regulation or enhancement of antigen function may be useful in the induction of tumor immunity.
  • Tumor cells e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma
  • a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides.
  • Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic ceUs that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol.
  • Assays for embryonic stem ceU differentiation include, without limitation, those described in: Johansson et al. CeUular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood
  • a protein of the invention may also exhibit one or more of the foUowing additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or caricadic cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting
  • the amount of protein of the present invention in the pharmaceutical composition of the present invention wUl depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further.
  • ATTATCCTGT ATTCCTTTGG CTTGGCATCT TTTAGCTCAG GAAGGTAGAA GAGATCTGTG 1560

Abstract

L'invention concerne de nouveaux polynucléotides et les protéines qui sont codées par ces polynucléotides.
PCT/US1998/002767 1997-02-14 1998-02-13 Proteines secretees et polynucleotides les codant WO1998036067A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP98906384A EP0981612A2 (fr) 1997-02-14 1998-02-13 Proteines secretees et polynucleotides les codant
JP53592498A JP2002514070A (ja) 1997-02-14 1998-02-13 分泌タンパク質およびそれをコードするポリヌクレオチド
AU61622/98A AU6162298A (en) 1997-02-14 1998-02-13 Secreted proteins and polynucleotides encoding them
CA002280968A CA2280968A1 (fr) 1997-02-14 1998-02-13 Proteines secretees et polynucleotides les codant

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80041897A 1997-02-14 1997-02-14
US08/800,418 1997-02-14
US2269298A 1998-02-12 1998-02-12
US09/022,692 1998-02-12

Publications (3)

Publication Number Publication Date
WO1998036067A2 WO1998036067A2 (fr) 1998-08-20
WO1998036067A3 WO1998036067A3 (fr) 1999-01-14
WO1998036067A9 true WO1998036067A9 (fr) 1999-02-18

Family

ID=26696248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/002767 WO1998036067A2 (fr) 1997-02-14 1998-02-13 Proteines secretees et polynucleotides les codant

Country Status (4)

Country Link
EP (1) EP0981612A2 (fr)
JP (1) JP2002514070A (fr)
CA (1) CA2280968A1 (fr)
WO (1) WO1998036067A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2344712A1 (fr) * 1998-10-01 2000-04-06 Zymogenetics, Inc. Proteine secretoire 48

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby

Similar Documents

Publication Publication Date Title
CA2269755A1 (fr) Proteines secretees et polynucleotides codant ces proteines
WO1998049302A1 (fr) Proteines secretees et polynucleotides les codant
CA2274732A1 (fr) Proteines secretees et polynucleotides codant pour lesdites proteines
EP0971950A2 (fr) Proteines secretees et polynucleotides les codant
CA2278770A1 (fr) Proteines secretees et polynucleotides les codant
WO1997046682A2 (fr) Polynucleotides issus des proteines secretees par l'adultes humains et codant pour les pbmc
WO1999007840A1 (fr) Proteines secretees et polynucleotides les codant
EP1062233A1 (fr) Proteines secretees et polynucleotides les codant
EP0996721A2 (fr) Proteines secretees et polynucleotides les codant
EP0972026A2 (fr) Proteines secretees et polynucleotides codant ces proteines
CA2273845A1 (fr) Proteines secretees et polynucleotides les codant
EP0968287A2 (fr) Proteines secretees et polynucleotides codant pour celles-ci
EP1007660A2 (fr) Proteines secretees et polynucleotides les codant
EP1032594A1 (fr) Proteines secretees et polynucleotides les codant
WO1998036067A9 (fr) Proteines secretees et polynucleotides les codant
WO1998036067A2 (fr) Proteines secretees et polynucleotides les codant
EP1032652A1 (fr) Proteines secretees et polynucleotides codant ces proteines
WO1999047555A1 (fr) Proteines secretees et polynucleotides les codant
WO1998030584A2 (fr) Proteines secretees et polynucleotides les codant
WO1998053065A1 (fr) Semaphorine e d'origine humaine et polynucleotides codant cette semaphorine e
EP0939805A2 (fr) Proteines secretees et polynucleotides codant pour celles-ci
EP1044220A1 (fr) Proteines secretees et polynucleotides les codant
CA2309007A1 (fr) Proteines secretees et polynucleotides les codant
CA2295212A1 (fr) Proteines secretees et polynucleotides codant ces proteines
EP0915971A2 (fr) Polynucleotides issus des proteines secretees par l'adultes humains et codant pour les pbmc
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载